Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine
| Autor: | Sergio Abrignani, Kathelyn S. Steimer, Joelle Wintsch, Barbara Doe, Jean Michel Dayer, Theophil Staehelin, Dietmar G. Braun, Dino Dina, Philippe Moret, Freddy Clavijo, Hans Stalder, Daniela Montagna, Michel Jeannet, André Cruchaud, Claire Lise Chaignat |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male medicine.medical_treatment viruses T-Lymphocytes Blotting Western Immunoblotting Enzyme-Linked Immunosorbent Assay Biology HIV Antibodies HIV Envelope Protein gp120 Lymphocyte Activation Antiviral Agents Virus Immune system Antigen Adjuvants Immunologic medicine Immunology and Allergy Humans Vaccines Synthetic Immunogenicity Phosphatidylethanolamines Antibody titer virus diseases Viral Vaccines Drug Tolerance Middle Aged Virology Vaccination Infectious Diseases Immunization Immunology HIV-1 Leukocytes Mononuclear Drug Evaluation Adjuvant Acetylmuramyl-Alanyl-Isoglutamine |
| Zdroj: | The Journal of infectious diseases. 163(2) |
| ISSN: | 0022-1899 |
| Popis: | A phase 1 trial of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine was done in 25 healthy seronegative subjects. The antigen, env2-3 (SF2), was a nonglycosylated polypeptide representing the gp120 region of the env gene of the HIV-1(SF2) isolate. It was produced in genetically engineered yeast as a denatured molecule incapable of binding CD4. A synthetic lipophilic muramyl tripeptide (MTP-PE) was used as an adjuvant. Ten subjects received adjuvant alone and 15 received 50- or 250-micrograms doses of env2-3 (SF2) administered intramuscularly in two immunization regimens. In general, adjuvant and vaccine were well tolerated. Antibody responses to both the homologous antigen, env2-3 (SF2), and antigens from other highly divergent HIV isolates were elicited in the majority of vaccine recipients. However, antibody titers were low, without neutralizing activity. In 9 of 11 subjects who received the complete vaccine immunization series, a significant specific T lymphocyte response was observed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|